Enhancement of carboplatin toxicity by Pluronic block copolymers

被引:69
作者
Exner, AA [1 ]
Krupka, TM [1 ]
Scherrer, K [1 ]
Teets, JM [1 ]
机构
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Radiol, Sch Med, Cleveland, OH 44106 USA
关键词
Pluronic block copolymers; carboplatin; cytotoxicity; sensitizer;
D O I
10.1016/j.jconrel.2005.04.015
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The objective of this study was to examine the effects of three Pluronic triblock copolymers (17127, P85, or L61) on the cytotoxicity of carboplatin to the DHB/K12/TRb rat colorectal carcinoma cell line. Studies to determine the dependence of the sensitization effect on Pluronic dose were carried out for polymer concentrations ranging from 0.0001-10% (w/w). To establish the carboplatin toxicity and its potential enhancement by Pluronic, the drug was delivered to cells in doses ranging from 0-0.5% (w/w) in the presence of Pluronic at a constant concentration. These treatment groups were compared to control groups receiving carboplatin alone. Cell cytotoxicity resulting from the treatments was determined with a mitochondrial enzyme activity assay (WST-1), while cell morphology was examined with May-Grunwald and Giemsa staining. Results indicate that the greatest enhancement of carboplatin toxicity was induced by P85, where the inhibitory concentration (IC50) was reduced by 50% (from 0.096 mg/mL for carboplatin alone to 0.048 mg/mL in presence of P85). L61 was toxic to the cells with or without drug (viability < 3.5%), while F127 exhibited no sensitizing effect and in some cases increased the cell viability to 130% over the untreated control. The WST-1 results were confirmed by trypan blue exclusion cell counts at 0 and 24 h post treatment. Data conclusively demonstrate that Pluronic P85 is the optimal agent for increased cytotoxicity of carboplatin in this cell line and can potentially be used not only as a drug delivery scheme but also as a chemosensitizing agent in future cancer therapy. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 26 条
[11]   Clinical pharmacokinetics and dose optimisation of carboplatin [J].
Duffull, SB ;
Robinson, BA .
CLINICAL PHARMACOKINETICS, 1997, 33 (03) :161-183
[12]  
Duvillard C, 1999, INT J CANCER, V81, P779, DOI 10.1002/(SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO
[13]  
2-I
[14]   Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery [J].
Goldberg, EP ;
Hadba, AR ;
Almond, BA ;
Marotta, JS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (02) :159-180
[15]   Local drug delivery [J].
Haroun, RI ;
Brem, H .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (03) :187-193
[16]   Toxicity of platinum compounds [J].
Hartmann, JT ;
Lipp, HP .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (06) :889-901
[17]   Pluronic® block copolymers for overcoming drug resistance in cancer [J].
Kabanov, AV ;
Batrakova, EV ;
Alakhov, VY .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :759-779
[18]   Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery [J].
Kabanov, AV ;
Batrakova, EV ;
Alakhov, VY .
JOURNAL OF CONTROLLED RELEASE, 2002, 82 (2-3) :189-212
[19]   Ionophoric activity of pluronic block copolymers [J].
Krylova, OO ;
Pohl, P .
BIOCHEMISTRY, 2004, 43 (12) :3696-3703
[20]   SELECTION BY TRYPSIN OF 2-SUBLINES OF RAT COLON CANCER-CELLS FORMING PROGRESSIVE OR REGRESSIVE TUMORS [J].
MARTIN, F ;
CAIGNARD, A ;
JEANNIN, JF ;
LECLERC, A ;
MARTIN, M .
INTERNATIONAL JOURNAL OF CANCER, 1983, 32 (05) :623-627